| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0004 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0004 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0005 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0006 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.19 | 0.0006 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0006 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | -0.1 | 0.0007 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0007 |